SCHEMBL22309012

SCHEMBL22309012

c1ccc(-c2nc(-c3cccc(-c4cccc(-c5nc(-c6ccc7ccccc7c6)nc(-c6ccc7ccccc7c6)n5)c4)c3)cc(-c3ccc4ccccc4c3)n2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A1 P04798 1/20 0.60
▸ CYP1B1 Q16678 1/20 0.60
▸ ALDH1A1 P00352 6/20 0.57
▸ MEN1 O00255 5/20 0.57
▸ KMT2A Q03164 5/20 0.57
▸ MAPT P10636 4/20 0.57
▸ HPGD P15428 4/20 0.57
▸ KDM4E B2RXH2 4/20 0.57
▸ LMNA P02545 2/20 0.57
▸ GLA P06280 1/20 0.57
▸ CYP1A2 P05177 3/20 0.54
▸ NTSR1 P30989 1/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ TP53 P04637 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ HSD17B1 P14061 1/20 0.49
▸ HSD17B2 P37059 1/20 0.49
▸ MAOB P27338 3/20 0.47
▸ CTRC Q99895 1/20 0.47
▸ CYP17A1 P05093 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22113747 1.00 CYP1A1 (0.60) CYP1A1CYP1B1ALDH1A1MEN1KMT2A
SCHEMBL22308904 0.98 CYP1A1 (0.58) CYP1A1CYP1B1ALDH1A1MEN1KMT2A
SCHEMBL22308868 0.98 CYP1A1 (0.58) CYP1A1CYP1B1ALDH1A1MEN1KMT2A
SCHEMBL22308869 0.98 CYP1A1 (0.58) CYP1A1CYP1B1ALDH1A1MEN1KMT2A
SCHEMBL22308867 0.98 CYP1A1 (0.58) CYP1A1CYP1B1ALDH1A1MEN1KMT2A
SCHEMBL22309759 0.98 CYP1A1 (0.63) CYP1A1CYP1B1ALDH1A1MEN1KMT2A
SCHEMBL22309762 0.98 CYP1A1 (0.58) CYP1A1CYP1B1ALDH1A1MEN1KMT2A
SCHEMBL22309621 0.98 CYP1A1 (0.63) CYP1A1CYP1B1ALDH1A1MEN1KMT2A
SCHEMBL22308550 0.98 CYP1A1 (0.63) CYP1A1CYP1B1ALDH1A1MEN1KMT2A
SCHEMBL22308761 0.97 CYP1A1 (0.61) CYP1A1CYP1B1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11917910-B2 Organic compound and organic electroluminescent device using the same SOLUS ADVANCED MATERIALS CO., LTD. (KR) 2024-02-27 — — US disclosed
US-11917910-B2 Organic compound and organic electroluminescent device using the same SOLUS ADVANCED MATERIALS CO., LTD. (KR) 2024-02-27 — — US disclosed
US-20200251659-A1 ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME DOOSAN CORPORATION (KR) 2020-08-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200251659-A1 ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME VDAC1, OR10J3, PIEZO1 CYP1A1 1223/4885CYP1B1 2080/4885ALDH1A1 644/4885
US-11917910-B2 Organic compound and organic electroluminescent device using the same VDAC1, OR10J3, PIEZO1 CYP1A1 1223/4885CYP1B1 2080/4885ALDH1A1 644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback